Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge

Journal of Heart and Lung Transplantation

Volumn 35, Issue 2, 2016, Pages 151-164

  Roldan, Tamara ^a   Landzberg, Michael J ^a,b   Deicicchi, David J ^a   Atay, Julie K ^a   Waxman, Aaron B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

anticoagulation; efficacy; pulmonary hypertension; safety; survival; vitamin K antagonists; warfarin

Indexed keywords

AMBRISENTAN; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BOSENTAN; CYTOCHROME P450 3A4; DABIGATRAN; EDOXABAN; ENOXAPARIN; HEPARIN; ILOPROST; IMATINIB; ISOPRENALINE; MACITENTAN; NIFEDIPINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROTEIN C; RIOCIGUAT; RIVAROXABAN; SILDENAFIL; SITAXSENTAN; TADALAFIL; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TREPROSTINIL; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR RISK; CENTRAL VENOUS CATHETER; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DISEASE SEVERITY; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEMOPTYSIS; HUMAN; IMMOBILITY; INDWELLING CATHETER; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SUBDURAL HEMATOMA; SURVIVAL; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; FEMALE; HYPERTENSION, PULMONARY; ORAL DRUG ADMINISTRATION; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 84959888940     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.10.002     Document Type: Article

References (88)

1. M.D. McGoon, R.L. Benza, P. Escribano-Subias, and et al. Pulmonary arterial hypertension: epidemiology and registries J Am Coll Cardiol 62 25 Suppl 2013 D51 D59
2. G. Simonneau, M.A. Gatzoulis, I. Adatia, and et al. Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 62 25 Suppl 2013 D34 D41
3. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N Engl J Med 351 2004 1425 1436
4. S.C. Wu, S. Caravita, E. Lisi, and et al. Pulmonary arterial hypertension Intern Emerg Med 4 2009 459 470
5. N.W. Morrell, S. Adnot, S.L. Archer, and et al. Cellular and molecular basis of pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl 2009 S20 S31
6. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). [e-pub ahead of print]. Eur Heart J. Available at: http://dx.doi.org/10.1093/eurheartj/ehv317. Accessed October 26, 2015.
7. V.V. McLaughlin, S.L. Archer, D.B. Badesch, and et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol 53 2009 1573 1619
8. N. Galie, P.A. Corris, A. Frost, and et al. Updated treatment algorithm of pulmonary arterial hypertension J Am Coll Cardiol 62 25 Suppl 2013 D60 D72
9. D.B. Taichman, J. Ornelas, L. Chung, and et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report Chest 146 2014 449 475
10. O. Storstein, L. Efskind, C. Müller, and et al. Primary pulmonary hypertension with emphasis on its etiology and treatment Acta Med Scand 179 1966 197 212
11. V. Fuster, P.M. Steele, W.D. Edwards, and et al. Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 1984 580 587
12. A.R. Tonelli, V. Arelli, O.A. Minai, and et al. Causes and circumstances of death in pulmonary arterial hypertension Am J Respir Crit Care Med 188 2013 365 369
13. P. Herve, M. Humbert, O. Sitbon, and et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis Clin Chest Med 22 2001 451 458
14. M.M. Hoeper, M. Sosada, and H. Fabel Plasma coagulation profiles in patients with severe primary pulmonary hypertension Eur Respir J 12 1998 1446 1449
15. S.R. Johnson, J.T. Granton, and S. Mehta Thrombotic arteriopathy and anticoagulation in pulmonary hypertension Chest 130 2006 545 552
16. G. Berger, Z.S. Azzam, R. Hoffman, and et al. Coagulation and anticoagulation in pulmonary arterial hypertension Isr Med Assoc J 11 2009 376 379
17. C.H. Welsh, K.L. Hassell, D.B. Badesch, and et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension Chest 110 1996 710 717
18. P.R. Eisenberg, C. Lucore, L. Kaufman, and et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension Circulation 82 1990 841 847
19. I.R. Henkens, T. Hazenoot, A. Boonstra, and et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension Eur Respir J 41 2013 872 878
20. P. Jansa, I. Hrachovinova, D. Ambroz, and et al. Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension Bratisl Lek Listy 111 2010 595 598
21. G.S. Ngian, W. Stevens, D. Prior, and et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study Arthritis Res Ther 14 2012 R213
22. S.R. Johnson, J.T. Granton, G.A. Tomlinson, and et al. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors J Rheumatol 38 2011 462 469
23. N.H. Kim, M. Delcroix, D.P. Jenkins, and et al. Chronic thromboembolic pulmonary hypertension J Am Coll Cardiol 62 25 Suppl 2013 D92 D99
24. R. Romaszkiewicz, J. Lewczuk, P. Piszko, and et al. Results of one-year anticoagulation in patients with newly detected chronic thromboembolic pulmonary hypertension not treated with pulmonary endarterectomy Kardiol Pol 64 2006 1196 1202
25. S. Rich, E. Kaufmann, and P.S. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 1992 76 81
26. M. Ogata, M. Ohe, K. Shirato, and et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension Jpn Circ J 57 1993 63 69
27. H. Frank, J. Mlczoch, K. Huber, and et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension Chest 112 1997 714 721
28. A. Roman, J. Rodés-Cabau, B. Lara, and et al. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension Med Clin (Barc) 118 2002 761 766 [in Spanish]
29. S.M. Kawut, E.M. Horn, K.K. Berekashvili, and et al. New predictors of outcome in idiopathic pulmonary arterial hypertension Am J Cardiol 95 2005 199 203
30. S.R. Johnson, S. Mehta, and J.T. Granton Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review Eur Respir J 28 2006 999 1004
31. W. Saeed, N. Tiawari, M.R. Sardar, and et al. Effect of warfarin on long term pulmonary arterial hypertension (PAH) mortality: change of facts? Circulation 124 2011 A16034
32. S.R. Johnson, J.T. Granton, G.A. Tomlinson, and et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease J Rheumatol 39 2012 276 285
33. K.M. Olsson, M. Delcroix, H.A. Ghofrani, and et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) Circulation 129 2014 57 65
34. I.E. Preston, K.E. Roberts, D.P. Miller, and et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL) Am J Respir Crit Care Med 189 2014 A2464
35. I.R. Ezedunukwe, H. Enuh, J. Nfonoyim, and et al. Anticoagulation therapy versus placebo for pulmonary hypertension Cochrane Database Syst Rev 2014 6 CD010695
36. D. Caldeira, M.J. Loureiro, J. Costa, and et al. Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis Can J Cardiol 30 2014 879 887
37. T.R. Gildea, A.C. Arroliga, and O.A. Minai Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension Cleve Clin J Med 70 Suppl 1 2003 S18 S27
38. S.H. Lee, and L.J. Rubin Current treatment strategies for pulmonary arterial hypertension J Intern Med 258 2005 199 215
39. N. Galie, A. Torbicki, R. Barst, and et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur Heart J 25 2004 2243 2278
40. D.B. Badesch, S.H. Abman, G.S. Ahearn, and et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 1 Suppl 2004 35S 62S
41. S. Suissa, and N. Galié Letter by Suissa and Galié regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA)." Circulation 130 2014 e107
42. D.B. Badesch, S.H. Abman, G. Simonneau, and et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines Chest 131 2007 1917 1928
43. M. Humbert, O. Sitbon, A. Chaouat, and et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
44. D.B. Badesch, G.E. Raskob, C.G. Elliott, and et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry Chest 137 2010 376 387
45. M. Nikpour, W. Stevens, S.M. Proudman, and et al. Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated? Intern Med J 43 2013 599 603
46. R.J. Barst, S.I. Ertel, M. Beghetti, and et al. Pulmonary arterial hypertension: a comparison between children and adults Eur Respir J 37 2011 665 677
47. D. Ivy, and B.T. Saji A new era in medical management of severe pediatric pulmonary arterial hypertension Nihon Shoni Junkanki Gakkai Zasshi 26 2010 206 218
48. J. Sandoval, L.E. Santos, J. Cordova, and et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? Congenit Heart Dis 7 2012 268 276
49. D. Garcia, E. Libby, and M.A. Crowther The new oral anticoagulants Blood 115 2010 15 20
50. M. Delbeck, K.F. Nickel, E. Perzborn, and et al. A role for coagulation factor Xa in experimental pulmonary arterial hypertension Cardiovasc Res 92 2011 159 168
51. ClinicalTrials.gov. Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS). Available at: https://clinicaltrials.gov/ct2/show/NCT02157272. Accessed December 17, 2014.
52. C.T. Ruff, R.P. Giugliano, E. Braunwald, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials Lancet 383 2014 955 962
53. L. Bertoletti, X. Delavenne, D. Montani, and et al. Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Eur Respir J 40 Suppl 56 2012 P1510
54. P. Gallego, S. Apostolakis, and G.Y. Lip Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation Circulation 126 2012 1573 1576
55. J.D. Douketis, A.C. Spyropoulos, F.A. Spencer, and et al. Perioperative management of antithrombotic therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e326S
56. S.M. Bates, I.A. Greer, S. Middeldorp, and et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e691S e6736
57. C.F. Opitz, W. Kirch, E.A. Mueller, and et al. Bleeding events in pulmonary arterial hypertension Eur J Clin Invest 39 Suppl 2 2009 68 73
58. R.A. Chaer, M.G. Massad, A. Evans, and et al. Systemic sclerosis complicated by diffuse alveolar hemorrhage Med Sci Monit 7 2001 1013 1015
59. H. Badsha, C.L. Teh, K.O. Kong, and et al. Pulmonary hemorrhage in systemic lupus erythematosus Semin Arthritis Rheum 33 2004 414 421
60. C.K. Silversides, J.T. Granton, E. Konen, and et al. Pulmonary thrombosis in adults with Eisenmenger syndrome J Am Coll Cardiol 42 2003 1982 1987
61. R. Pisters, D.A. Lane, R. Niewlaat, and et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
62. G.J. Merli, and G. Tzanis Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis 27 2009 293 299
63. M. Jones, P. McEwan, C.L. Morgan, and et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart 91 2005 472 477
64. E.M. Hylek, A.S. Go, Y. Chang, and et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
65. C. Sarawate, M.V. Sikirica, V.J. Willey, and et al. Monitoring anticoagulation in atrial fibrillation J Thromb Thrombolysis 21 2006 191 198
66. D.M. Witt, M.A. Sadler, R.L. Shanahan, and et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy Chest 127 2005 1515 1522
67. N.J. Veeger, M. Piersma-Wichers, H.L. Hillege, and et al. Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease J Thromb Haemost 4 2006 1625 1627
68. C.L. Morgan, P. McEwan, A. Tukiendorf, and et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control Thromb Res 124 2009 37 41
69. A.M. Gallagher, E. Setakis, J.M. Plumb, and et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients Thromb Haemost 106 2011 968 977
70. C. Schmidt-Lucke, W.D. Paar, C. Stellbrink, and et al. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial Thromb Res 119 2007 27 34
71. H.D. White, M. Gruber, J. Feyzi, and et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch Intern Med 167 2007 239 245
72. Flolan (epoprostenol sodium) for injection. Full prescribing information. Available at: http://us.gsk.com/products/assets/us-flolan.pdf. Accessed March 27, 2014.
73. R.J. Barst, G. Maislin, and A.P. Fishman Vasodilator therapy for primary pulmonary hypertension in children Circulation 99 1999 1197 1208
74. A. Ogawa, H. Matsubara, H. Fujio, and et al. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension - anticoagulation and epoprostenol therapy Circ J 69 2005 216 220
75. G. Simonneau, R.J. Barst, N. Galie, and et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
76. T. Roldan, L. Deiros, J.A. Romero, and et al. Safety and tolerability of targeted therapies for pulmonary hypertension in children Pediatr Cardiol 35 2014 490 498
77. L.J. Rubin, D.B. Badesch, R.J. Barst, and et al. Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
78. H.A. Ghofrani, A.M. D'Armini, F. Grimminger, and et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension N Engl J Med 369 2013 319 329
79. R. Frey, W. Mück, N. Kirschbaum, and et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study J Clin Pharmacol 51 2011 1051 1060
80. M.M. Hoeper, R.J. Barst, R.C. Bourge, and et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension results of the randomized IMPRES study Circulation 127 2013 1128 1138
81. H. Mucke The role of imatinib in the treatment of pulmonary hypertension Drugs Today (Barc) 49 2013 203 211
82. S.M. Olsson, N.P. Nickel, J. Tongers, and et al. Atrial flutter and fibrillation in patients with pulmonary hypertension Int J Cardiol 167 2013 2300 2305
83. V.Y. Reddy, H. Sievert, J. Haperin, and et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized control trial JAMA 312 2014 1988 1998
84. D.C. Peritz, and E.H. Chung Left atrial appendage closure: an emerging option in atrial fibrillation when oral anticoagulants are not tolerated Cleve Clin J Med 82 2015 167 176
85. R.O. Bonow, B.A. Carabello, K. Chatterjee, and et al. 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation 118 2008 e523 e661
86. S. Saba Left atrial appendage closure: killing 2 birds with 1 stone? J Am Heart Assoc 4 2015 1 2
87. I.M. Robbins, S.M. Kawut, D. Yung, and et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension Eur Respir J 27 2006 578 584
88. S.M. Kawut, E. Bagiella, D.J. Lederer, and et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT Circulation 123 2011 2985 2993